Skip to content
Peptide research

Palmitoyl Dipeptide-6

Also known as Pal-Lys-Val · Syn-Tacks
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

A palmitoylated dipeptide marketed in anti-aging serums to firm skin, smooth crow's feet, and rebuild the dermal-epidermal junction. Evidence is almost entirely mechanistic and in vitro; human proof of real wrinkle or firmness improvement is speculative. The palmitoyl chain aids penetration, not efficacy. Safety data are limited, and excipient allergy is a real, moderate risk. It is a cosmetic ingredient, not an FDA-approved drug, subject to FDA cosmetic requirements.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Stimulation of dermal-epidermal junction (DEJ) structural proteins (Collagen IV, VII, XVII, Laminin V, Integrin beta-4)

    Speculative

    A related lipopeptide raised laminin and collagen IV/XVII in skin cells; this molecule is untested.

  • Reduction in fine lines and wrinkles, particularly periorbital crow's feet

    Speculative

    No published trials; wrinkle claims come from unpublished, multi-ingredient manufacturer testing.

  • Improved skin firmness, compactness, and elasticity

    Speculative

    Inferred from proposed matrix protein effects; no human elasticity or firmness data exist.

Evidence limits

Evidence Level
Preclinical

Clinical evidence for Palmitoyl Dipeptide-6 is limited to manufacturer-sponsored cosmetic evaluations and small studies of other peptides. No independent, large-scale, randomized, placebo-controlled clinical trials have been published specifically for this ingredient. The DSM SYN-TACKS clinical program tested the peptide combination at 1% concentration over 56-84 days and reported improvements in skin compactness, wrinkle reduction, and tonicity, but detailed methodology, sample sizes, and statistics are available only in proprietary brochures rather than peer-reviewed publications. Published studies of the distinct palmitoyl-KVK-L-ascorbic acid conjugate (PMID 28303328) and of a different complex of biotinylated and ascorbyl-linked peptides (PMID 31861912) reported wrinkle improvement in small human trials (n=22-32), but they tested different ingredients. CIR deferred the broad 2013 assessment for regrouping; it did not establish this ingredient's safety.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(3)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Contact dermatitis or skin irritation (theoretical)

    Low
  • Limited long-term safety data

    Low
  • Allergic reaction to formulation excipients

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.